ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2009
Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 57 citations in OpenAlex.
- Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.Annals of the American Thoracic Society · 2014Trial
- Mixed infection withFrontiers in medicine · 2026Article
- Characterizing species-specific metabolic signatures in vaginal microbiota across planktonic and biofilm states.Biofilm · 2025Article
- Effective therapeutic strategies against Pseudomonas aeruginosa and Burkholderia Cepacia complex infections.Scientific reports · 2025Article
- Low- versus high-dose trimethoprim-sulfamethoxazole for the treatment ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Subtractive sequence analysis aided druggable targets mining in Burkholderia cepacia complex and finding inhibitors through bioinformatics approach.Molecular diversity · 2023Article
- Biocontrol of biofilm forming Burkholderia cepacia using a quorum quenching crude lactonase enzyme extract from a marine Chromohalobacter sp. strain D23.Archives of microbiology · 2023Article
- Lung Transplantation in a New Era in the Field of Cystic Fibrosis.Life (Basel, Switzerland) · 2023Review
- Promising Therapeutic Strategies Against Microbial Biofilm Challenges.Frontiers in cellular and infection microbiology · 2020Review
- RefractoryBMJ case reports · 2019Article
- Short Palate, Lung, and Nasal Epithelial Clone 1 Has Antimicrobial and Antibiofilm Activities against the Burkholderia cepacia Complex.Antimicrobial agents and chemotherapy · 2016Article
- Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating Carriers.Pharmaceutical research · 2016Article
- Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Seminars in respiratory and critical care medicine · 2015Review
- Potential of metabolomics to reveal Burkholderia cepacia complex pathogenesis and antibiotic resistance.Frontiers in microbiology · 2015Review
- Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.Antimicrobial agents and chemotherapy · 2014Article
- Development and antimicrobial susceptibility studies of in vitro monomicrobial and polymicrobial biofilm models with Aspergillus fumigatus and Pseudomonas aeruginosa.BMC microbiology · 2014Article
- Two quorum sensing systems control biofilm formation and virulence in members of the Burkholderia cepacia complex.Virulence · 2013Review
- Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.Antimicrobial agents and chemotherapy · 2013Article
- In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.The Journal of antimicrobial chemotherapy · 2012Article
- A rare case of community acquired Burkholderia cepacia infection presenting as pyopneumothorax in an immunocompetent individual.Asian Pacific journal of tropical biomedicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We identified double and triple antibiotic combinations effective against biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa sampled from cystic fibrosis (CF) patients undergoing acute pulmonary exacerbations. Sputum bacteria from 110 CF patients were grown as biofilms. Combination antibiotic susceptibility testing was used to test 94 double and triple antibiotic combinations. Biofilm-grown bacterial isolates were less susceptible to antibiotic combinations compared to the same bacterial isolates grown planktonically (P < 0.001). Fifty-nine percent of biofilm-grown B. cepacia isolates and 29% of P. aeruginosa isolates were resistant to all double antibiotic combinations tested. Triple antibiotic combinations were more effective than double antibiotic combinations against biofilms (P < 0.0001). For P. aeruginosa biofilms, the addition of azithromycin or rifampin to otherwise effective antibiotic combinations was frequently associated with antagonism. Bacterial biofilms of CF organisms are highly resistant to antibiotics. This study identified potentially effective antibiotic combinations to guide the empirical treatment of CF pulmonary exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.